Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMCOVAS: Adapted COVID-19 Vaccine Schedules and Routes
NCT06189040Phase 4Completed
- Sponsor
- University of Antwerp
- Start
- May 2021
- Primary completion
- Nov 2021
- Modality
- Viral Vector Vaccines, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of tozinameran, elasomeran, ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19), sponsored by University of Antwerp. Started May 2021; status: completed.
02
Drugs
tozinameranelasomeranChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06189040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06189040.